Director William JL Rieflin filed a Form 4 with the SEC on October 26, 2026, reporting the acquisition of two stock option grants from Lycia Therapeutics, Inc. (NASDAQ:LYCA), covering transactions dated August 11, 2026 and October 22, 2026.

Key Highlights

  • First option grant: 24,840 stock options (right to buy common stock) acquired on August 11, 2026, at an exercise price of $3.70, with an expiration date of August 10, 2036.
  • Second option grant: 20,000 stock options acquired on October 22, 2026, at an exercise price of $18.00, with an expiration date of October 21, 2036.
  • Zero cost at grant: Both option awards were reported at a price of $0 at the time of acquisition.
  • Vesting schedules differ: The 24,840-share grant vests 1/48 monthly over four years; the 20,000-share grant vests 100% on October 22, 2027.
  • Pre-IPO transaction noted: The August 11, 2026 transaction occurred prior to the issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the issuer's initial public offering.
  • Reporting person's role: William JL Rieflin is identified as a Director of Lycia Therapeutics, Inc.

Director Rieflin's Option Awards: Details From the Filing

According to the Form 4 filed October 26, 2026, William JL Rieflin, a director of Lycia Therapeutics, Inc. (NASDAQ:LYCA), reported two separate acquisitions of stock options. The first grant, consisting of 24,840 stock options with a right to buy common stock at $3.70 per share, was dated August 11, 2026, and expires August 10, 2036. The filing notes that this transaction occurred prior to the issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the issuer's initial public offering, and is reported pursuant to Rule 16a-2(a).

The vesting schedule for the 24,840-share grant, as disclosed in the filing, calls for options to vest as to 1/48 of the total award monthly over four years, with the first tranche having vested on September 6, 2026, subject to the reporting person's continued provision of service to the issuer on each vesting date. The second grant of 20,000 stock options, with an exercise price of $18.00 per share and an expiration of October 21, 2036, was awarded on October 22, 2026. The filing states these options will vest as to 100% of the award on October 22, 2027, also subject to continued service.

Both awards are held directly by Rieflin, according to the filing. Following these transactions, the filing reports Rieflin beneficially owns 24,840 derivative securities from the first grant and 20,000 from the second grant. The form was signed by Amy Bachrodt as Attorney-in-Fact on October 26, 2026.

What Was Disclosed

Lycia Therapeutics director William JL Rieflin reported two stock option grants totaling 44,840 options in a Form 4 filed October 26, 2026, covering transactions on August 11, 2026 and October 22, 2026, with exercise prices of $3.70 and $18.00 respectively.